-
2 weeks ago | 
bioxconomy.com | Søren Hough |Josh Abbott
At an FDA round table, cell, gene, and genome editing therapy stakeholders brainstormed ways to get treatments to patients faster. But will Washington listen? Advanced therapies appear to be turning a corner after facing a rocky investment landscape in 2024. In the past few weeks, researchers used CRISPR base editing to successfully treat a baby named KJ who was born with a fatal metabolic disorder.
-
1 month ago | 
bioprocessintl.com | James Choi |Josh Abbott |Shreeyashi Ojha |Dan Stanton
Planning for commercial biologic manufacturing is challenging, not least because it requires considerable time, investment, and economic risk. As global demand for biopharmaceuticals climbs, drug companies will need to be resourceful to ensure that their products will be manufactured at sufficient volumes and in the desired markets. This eBook places bioproduction capacity in the spotlight, highlighting options that biologics developers can leverage as they seek to expand their global reach.
-
1 month ago | 
bioprocessintl.com | Dan Stanton |Josh Abbott
Imunon looks to DNA vaccine tech to support ovarian cancer immunotherapyDepositPhotos/drecunThe New Jersey-based biotech is developing non-viral DNA technology for various modalities. Its lead candidate is IMNN-001, an immunotherapy for ovarian cancer, based on the firm’s TheraPlas platform.
-
Feb 18, 2025 | 
bioprocessintl.com | Josh Abbott |Shreeyashi Ojha
In a 53-47 vote that fell entirely across party lines, Robert F. Kennedy Jr. was confirmed by the US Senate to lead the Department of Health and Human Services as secretary. Ultimately, the few Republican senators such as Bill Cassidy (R-LA), who had expressed skepticism in President Donald Trump’s pick, fell in line, making official the result that analysts expected.
-
Jan 15, 2025 | 
bioprocessintl.com | Josh Abbott
Samarth Kulkarni, CEO of CRISPR Therapeutics, spoke at the JP Morgan Healthcare Conference about his firm’s development of allogeneic therapies and their manufacturing and cost advantages compared with autologous therapies.
-
Jan 10, 2025 | 
bioprocessintl.com | Josh Abbott
Contract development and manufacturing organization (CDMO) Samsung Biologics extended its partnership with Korea-based biopharmaceutical development firm LigaChem Biosciences to provide antibody-drug conjugate (ADC) services. The extension stems from an agreement first signed by the two companies in February 2024. A spokesperson for Samsung Biologics told BioProcess Insider that the companies will collaborate on three projects for the development of ADC therapies.
-
Jan 8, 2025 | 
bioprocessintl.com | Josh Abbott
Under terms of the deal, Poseida will become a wholly owned subsidiary of Swiss pharmaceutical giant Roche. Josh Abbott, Editor, BioProcess InsiderRoche Holding AG is acquiring clinical-stage cell and gene therapy (CGT) developer Poseida Therapeutics in the finalization of a $1.5 billion deal first announced in December 2024.
-
Jan 8, 2025 | 
bioprocessintl.com | Josh Abbott
“In the US, fewer than 5% of hospitals have the experience and capabilities needed to manage and administer advanced cellular therapies,” said Jeff Wren, VP of biotherapies for Association for the Advancement of Blood & Biotherapies (AABB).
-
Jan 7, 2025 | 
bioprocessintl.com | Josh Abbott
In the mRNA vaccine maker’s 2024 Shareholder Letter, CEO Stéphane Bancel reflected upon the company’s second year manufacturing and distributing vaccines for COVID-19, admitting that sales in the US have declined due to increased market competition while global sales have had a mixed performance. To counter such issues, the company is looking to decrease research and development (R&D) expenditures and drive efficient manufacturing.
-
Dec 9, 2024 | 
bioprocessintl.com | Josh Abbott
Passage of the BIOSECURE Act has been delayed after being excluded from the end-of-year defense spending bill that the US government unveiled over the weekend. If passed into law, the BIOSECURE Act would restrict certain named Chinese companies from doing business with and receiving funding from the US government. Contract development and manufacturing organization (CDMO) WuXi Biologics and biopharmaceutical and medical device company WuXi Apptec are among those companies named in the Act.
